Contact us Demo our platform

Blog

Short Chain Fatty Acids Metabolism

Short Chain Fatty Acids Metabolism

Short chain fatty acids (SCFAs) have been the focus of intense study for years due to their ability to improve gut health.1 SCFAs are produced in the colon by microbial fermentation of fiber—one of the main reasons increased consumption of fiber is recommended to increase gut health—and have been used to alleviate symptoms of several gut disorders.2,3 The most abundant SCFAs in the colon are butyrate, propionate, and acetate,2 each produced by a different set of bacteria,3,4 and each with a different physiological contribution to gut function and health.

SCFAs and Gut Health

SCFAs have a range of reported health benefits, including increased gut barrier function, increased liver metabolism, reduction of inflammatory bowel disease (IBD)-associated symptoms, promotion of immune tolerance and anti-inflammatory immune responses, regulation of lipid, cholesterol, and glucose metabolism, and protection against some cancers including colorectal and liver.5 

The most well-studied SCFA, butyrate, is a critical energy source for colonocytes, helps maintain gut barrier integrity, helps protect the gut barrier, and regulates mucus production (which further influences gut barrier function)3—all important for appropriate nutrient absorption and prevention of inappropriate immune responses. 

Butyrate and acetate also influence appetite by regulating gut hormones and, in the case of acetate, crossing the blood-brain barrier to impact appetite signals sent and received by the hypothalamus.1,3,6 Acetate and propionate have also been implicated in insulin secretion and blood glucose control as well as the regulation of lipolysis and adipogenesis.1,3 SCFAs, particularly butyrate, can also improve gut motility.6

SCFAs and the Microbiome

While the beneficial effects of SCFAs have historically been attributed to fiber, the past five to ten years of microbiome research have increasingly demonstrated the critical role played by the human microbiome in not only SCFA production, but also the regulation of hormones (particularly those playing a role in the gut-brain axis). 

The relationship between the gut microbiome and SCFAs appears to be bidirectional, with the presence of SCFAs regulating further production by changing the pH of the intestinal milieu and favoring the production of propionate and acetate over butyrate.2 And diet—unsurprisingly, given the central role of fiber in SCFA production—directly and significantly impacts SCFA production through modulation of the gut microbiome.3 

The human microbiome is now the not-so-missing link between fiber consumption and the many benefits associated with fiber. Because the production of SCFAs is the result of bacterial metabolism, an increasing number of studies are utilizing metabolomics approaches to deeply investigate SCFA production and the impact of SCFAs on human health. 

Metabolon’s suite of products, including the Global Discovery Panel and Complex Lipids, Bile Acids, and SCFA Targeted Panels have supported several of the seminal papers using metabolomics to deeply characterize the intricate relationship between the gut microbiome and human health.8-12 Some of these studies, with their deeper, phenotypic resolution, suggest that SCFAs might not always be good.

When Are SCFAs Harmful?

A growing body of evidence, centered around microbiome metabolomics, demonstrates that SCFAs aren’t always beneficial. For example, research has provided a connection between the microbiome, SCFAs, and the link between IBD and liver conditions such as autoimmune hepatitis and primary sclerosing cholangitis.13 

Using an ex vivo model of ulcerative colitis, the study authors replicated several positive impacts of SCFA but additionally revealed a proinflammatory impact of SCFAs during acute T cell-mediated inflammation.13 Metabolomics analysis using the Metabolon Discovery Panel and the SCFA Targeted Panel revealed that this paradoxical finding was due in part to metabolic reprogramming that further caused gut barrier dysfunction and injury to liver cells.13

Metabolon’s Microbiome Portfolio

Metabolon is proud to help advance our understanding of the human microbiome and how it impacts human health. Our SCFA and Bile Acids Targeted Panels, which detect microbially-derived metabolites of interest, are a powerful add-on to our Global Discovery and Complex Lipids Targeted Panels. Together, this suite of panels targets hundreds of microbially-derived metabolites across over a dozen pathways including bile acid metabolism, sulfur metabolism, nitrogen metabolism, vitamin B metabolism, and more, and can place them in the context of host metabolism (using the untargeted metabolomics Global Discovery Panel). Our decades of experience and unmatched metabolite databases can help you maximize the discovery potential of your microbiome research projects. Contact us today to learn more about how Metabolon can help you advance your microbiome studies.

Contact us today to learn more.

References

  1. Martin-Gallausiaux C, Marinelli L, and Blottière M. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80(1):37—49. doi: 10.1017/S0029665120006916
  2. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DK, and Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325—2340. doi: 10.1194/jlr.R036012
  3. Nogal A, Valdes AM, and Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut Microbes. 2021;13(1):1897212. doi: 10.1080/19490976.2021.1897212
  4. Macfarlane S and Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003;62(1):67—72. doi: 10.1079/PNS2002207
  5. Ohtani N and Hara E. Gut‐liver axis‐mediated mechanism of liver cancer: A special focus on the role of gut microbiota. Cancer Sci. 2021;112(11): 4433–4443. doi: 10.1111/cas.15142
  6. Fernández-Bello I, Monzón Manzano E, García Río F, Justo Sanz R, Cubillos-Zapata C, Casitas R, et al. A.Procoagulant state of sleep apnea depends on systemic inflammation and endothelial damage. Arch Bronconeumol. 2022;58(2):117—124. doi: 10.1016/j.arbres.2020.11.017
  7. Canani RB, Di Costanzo M, Leone L, Pedata M, Meli R, and Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(2):1519—1528. doi: 10.3748/wjg.v17.i12.1519
  8. Visconti A, Le Roy CI, Rosa F, Rossi N, Martin TC, Mohney RP et al. Interplay between the human gut microbiome and host metabolism. Nat Commun. 2019;10(1):4505. doi: 10.1038/s41467-019-12476-z.
  9. Henriques SF, Dhakan DB, Serra L, Francisco AP, Carvalho-Santos Z, Baltazar C et at. Metabolic cross-feeding in imbalanced diets allows gut microbes to improve reproduction and alter host behaviour. Nat Commun. 2020;11(1):4236. doi: 10.1038/s41467-020-18049-9
  10. Bao R, Hesser LA, He Z, Zhou X, Nadeau K, and Nagler C. Fecal microbiome and metabolome differ in healthy and food-allergic twins. J Clin Invest. 2021;131(2):e141935. doi: 10.1172/JCI141935
  11. Wastyk HC, Fragiadakis GK, Perelman D, Dahan D, Merrill BD, Yu FB et al. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021;184(16):4137-4153.e14. doi: 10.1016/j.cell.2021.06.019
  12. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360(6391):eaan5931. doi: 10.1126/science.aan5931
  13. Trapecar M, Communal C, Velazquez J, Maass CA, Huang YJ, Schneider K, et al. Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids. Cell Systems. 2020;10(3):223—239. doi: 10.1016/j.cels.2020.02.008
Lisa Ford, Ph.D.
Dr Lisa Ford is the Clinical Laboratory Director and the technical leader of the quantitative analysis team at Metabolon. Lisa has been with Metabolon since 2011 where she focuses on method development and performance of novel LC-MS/MS-based tests for endogenous metabolites within the Clinical and Targeted Analysis lab, as well as supervising the CAP/CLIA compliant diagnostic tests performed at Metabolon. She received her PhD in Bio-organic Chemistry from Duke University.

Topics

Gastrointestinal | Liver Disease | Microbiome | Population Health

Share this article

Related Blog Posts

See All Blog Posts

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.